Innovation Pharmaceuticals Inc (IPIX)

[rule_rationale]

Phase 3 anti-infective: 22.8 Million. I think that qualifies as many multiples less than 145 Million. And if this trial goes like all of Cellceutix's past trials (all of which have been successful) then the cost is likely to be even less than 22.8 Million. We know Cellceutix has proven to be below average cost and above average success based on their current track record.